ABBV-744 is a BDII domain-selective BET inhibitor, which is currently being evaluated in clinical trials for relapsed/refractory acute myeloid leukemia (AML) as well as in myelofibrosis (NCT03360006, NCT04454658) and has shown promising results in prostate cancer models [16]. The gene discussed is DNER; the disease is prostate cancer.